2-(正丙硫基)烟酸 | 175135-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(正丙硫基)烟酸
• 中文别名: 2-丙基硫代烟酸；2-(正丙基硫代)烟酸
• 英文名称: 2-propylsulfanylnicotinic acid
• 英文别名: 2-(propylthio)nicotinic acid；2-propylsulfanylpyridine-3-carboxylic acid
• CAS: 175135-22-5
• 化学式: C₉H₁₁NO₂S
• mdl: MFCD00051682
• 分子量: 197.258
• InChiKey: CSMDLVRDBYKTAH-UHFFFAOYSA-N

物化性质

• 熔点：
  159 °C
• 溶解度：
  >29.6 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  75.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	2-(Propylthio)nicotinic acid 97% Material Safety Data Sheet
Synonym:	2-(Propylthio)pyridine-3-carboxylic aci
CAS:	175135-22-5

Section 1 - Chemical Product MSDS Name:2-(Propylthio)nicotinic acid 97% Material Safety Data Sheet
Synonym:2-(Propylthio)pyridine-3-carboxylic aci

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175135-22-5	2-(Propylthio)nicotinic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175135-22-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 160 - 162 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11NO2S
Molecular Weight: 197

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175135-22-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Propylthio)nicotinic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 175135-22-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175135-22-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175135-22-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(正丙硫基)烟酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 C₉H₁₀ClNOS
  参考文献：
  名称：

  Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017)

  摘要：

  Inhibition of 11 beta-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. We report here the discovery of a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. Compound 11i (AZD4017) is an effective inhibitor of 11 beta-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development.

  DOI：

  10.1021/jm300592r
• 作为产物：
  描述：

  2-巯基烟酸 、 1-碘代丙烷 以to obtain the title compound (1.22 g, 96%)的产率得到2-(正丙硫基)烟酸
  参考文献：
  名称：

  Thioaryl derivatives as GPR120 agonists

  摘要：

  本发明涉及公式1中定义的硫代芳基衍生物，其制备方法，包括其的药物组合物以及使用方法。本发明的公式1中的硫代芳基衍生物可以促进胃肠道中的GLP-1形成，并由于其抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗力，因此可以有效地用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。

  公开号：

  US09447044B2

文献信息

• [EN] BENZAMIDE TRPA1 ANTAGONISTS<br/>[FR] BENZAMIDES ANTAGONISTES DE TRPA1
  申请人：ACTURUM LIFE SCIENCE AB

  公开号：WO2014184235A1

  公开（公告）日：2014-11-20

  Compounds of formula I, pharmaceutically acceptable salts thereof, diastereomers, enantiomers, or mixtures thereof: wherein R, X, Y, Z, n and A are as defined in the specification, as well as pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

  式I的化合物，其药用盐，非对映体，对映体或其混合物：其中R、X、Y、Z、n和A的定义如规范中所述，以及包括这些化合物的药物组合物已经准备好。它们在治疗中很有用，特别是在疼痛管理中。
• Antibiotic oxazolidinone derivatives
  申请人：Zeneca Ltd.

  公开号：US06365751B1

  公开（公告）日：2002-04-02

  The invention concerns a compound of the formula (I): wherein, for example: R1 is of the formula —NHC(═O)Rb wherein Rb is, for example, (1-4C)alkyl; R2 and R3 are hydrogen or fluoro; R2 and R3 are hydrogen or fluoro; D is O; R4 and R5 are hydrogen, (1-4C)alkyl or AR-oxymethyl; AR is phenyl or phenyl(1-4C)alkyl; R6 is hydrogen; >A—B— is of the formula >C═C(Ra)—, >CHCHRa—, or >C(OH)CHRa— (> represents two single bonds) wherein Ra is hydrogen or (1-4C)alkyl; and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.

  本发明涉及如下公式(I)的化合物：其中，例如：R1是如下公式的形式—NHC(═O)Rb，其中Rb例如为(1-4C)烷基；R2和R3是氢或氟；D是氧；R4和R5是氢，(1-4C)烷基或AR-甲氧基甲基；AR是苯基或苯基(1-4C)烷基；R6是氢；>A—B—是如下公式的形式>C═C(Ra)—, >CHCHR_a—, 或 >C(OH)CHR_a—（>代表两个单键），其中Ra是氢或(1-4C)烷基；以及它们的药用可接受盐；它们的制备过程；含有它们的药物组合物以及它们作为抗菌剂的用途。
• [EN] THIOARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE THIOARYLE À TITRE D'AGONISTES DE GPR120
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014069963A1

  公开（公告）日：2014-05-08

  The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

  本发明涉及规范中定义的Formula 1的硫代芳基衍生物，一种制备该衍生物的方法，包含该衍生物的药物组合物以及其用途。根据本发明，Formula 1的硫代芳基衍生物促进胃肠道中GLP-1的形成，并通过抗炎作用改善巨噬细胞、胰腺细胞等的胰岛素抵抗，因此可以有效用于预防或治疗糖尿病、糖尿病并发症、炎症、肥胖、非酒精性脂肪肝、脂肪性肝炎或骨质疏松症。
• Synthesis of Indomorphan Pseudo‐Natural Product Inhibitors of Glucose Transporters GLUT‐1 and ‐3
  作者：Javier Ceballos、Melanie Schwalfenberg、George Karageorgis、Elena S. Reckzeh、Sonja Sievers、Claude Ostermann、Axel Pahl、Magnus Sellstedt、Jessica Nowacki、Marjorie A. Carnero Corrales、Julian Wilke、Luca Laraia、Kirsten Tschapalda、Malte Metz、Dominik A. Sehr、Silke Brand、Konstanze Winklhofer、Petra Janning、Slava Ziegler、Herbert Waldmann

  DOI：10.1002/anie.201909518

  日期：2019.11.18

  Bioactive compound design based on natural product (NP) structure may be limited because of partial coverage of NP-like chemical space and biological target space. These limitations can be overcome by combining NP-centered strategies with fragment-based compound design through combination of NP-derived fragments to afford structurally unprecedented "pseudo-natural products" (pseudo-NPs). The design, synthesis

  基于天然产物（NP）结构的生物活性化合物设计可能会受到限制，因为部分覆盖了NP类化学空间和生物目标空间。通过将NP为中心的策略与基于片段的化合物设计相结合（通过组合NP衍生的片段来提供结构上空前的“伪天然产物”（pseudo-NPs）），可以克服这些局限性。描述了结合生物合成无关的吲哚和吗啡生物碱片段的吲哚吗啡假NP集合的设计，合成和生物学评估。通过选择性靶向和上调葡萄糖转运蛋白GLUT-1和GLUT-3，可以确定吲哚吗啡衍生物Glupin是有效的葡萄糖吸收抑制剂。谷氨酰胺抑制糖酵解，降低葡萄糖衍生的代谢物的水平，并减弱各种癌细胞系的生长。我们的发现强调了双重GLUT-1和GLUT-3抑制对有效抑制肿瘤细胞生长和抵消葡萄糖缺乏的细胞拯救机制的重要性。
• 티오니코틴아미드 스캐폴드를 포함하는 신규 화합물, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항바이러스용 조성물
  申请人：Institut Pasteur Korea 재단법인 한국파스퇴르연구소(120080553578) Corp. No ▼ 114422-0006023BRN ▼209-82-08323

  公开号：KR20180036419A

  公开（公告）日：2018-04-09

  본 발명은 티오니코틴아미드 스캐폴드를 포함하는 신규 화합물, 이의 거울상 이성질체, 부분 입체 이성질체 또는 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항바이러스용 조성물에 관한 것이다. 본 발명에 따른 화학식 1로 표시되는 신규한 화합물은 인플루엔자 바이러스에 대한 항바이러스 활성이 현저히 우수할 뿐만 아니라, 세포독성이 낮아 인체에 부작용이 적으므로, 이를 유효성분으로 함유하는 약학적 조성물은 인플루엔자 바이러스 감염에 의해 발병되는 질환의 예방 또는 치료에 유용하게 사용할 수 있다.

  本发明涉及一种包含硝基烟酰胺骨架的新化合物，其对流感病毒具有显著优越的抗病毒活性，同时细胞毒性低，对人体副作用小。该新化合物可作为有效成分包含在抗病毒配方中，用于预防或治疗由流感病毒感染引起的疾病。

表征谱图